All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @teeheefunnay on TikTok · 151s|Watch on TikTok

@teeheefunnay's GLP-1 claims about cholesterol, fact-checked

Tiffany Shu

TikTok creator

54.3K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide primarily work as appetite suppressants through gut hormone mimicry. Clinical trials show 14.9% average weight loss with semaglutide 2.4mg over 68 weeks, with modest secondary effects on cholesterol and cardiovascular outcomes.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @teeheefunnay's GLP-1 claims about cholesterol, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@teeheefunnay's GLP-1 claims about cholesterol, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@teeheefunnay's GLP-1 claims about cholesterol, fact-checked" from Tiffany Shu. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide primarily work as appetite suppressants through gut hormone mimicry.

The reason this review is not generic is the source wording and the canonical claim label "glp1 the most vulnerable journey i ll be sharing online ive had." In this clip, the useful excerpt is: "The most vulnerable journey I'll be sharing online- Ive had an issue with my weight for my whole life… being too skinny then being too fat." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GLP-1s reduce LDL cholesterol by only 9.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide primarily work as appetite suppressants through gut hormone mimicry.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide primarily work as appetite suppressants through gut hormone mimicry. Clinical trials show 14.9% average weight loss with semaglutide 2.4mg over 68 weeks, with modest secondary effects on cholesterol and cardiovascular outcomes.
  • STEP 1 trial showed semaglutide 2.4mg caused 14.9% weight loss over 68 weeks, but 10-15% of people don't respond
  • GLP-1s reduce LDL cholesterol by only 9.6mg/dL compared to 30-50% reductions seen with statins

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • STEP 1 trial showed semaglutide 2.4mg caused 14.9% weight loss over 68 weeks, but 10-15% of people don't respond
  • GLP-1s reduce LDL cholesterol by only 9.6mg/dL compared to 30-50% reductions seen with statins
  • SELECT trial found 20% cardiovascular risk reduction, but this was likely due to weight loss rather than direct metabolic effects
  • About 5-10% of people stop GLP-1s due to gastrointestinal side effects like nausea and gastroparesis
  • Clinical criteria typically require BMI 30+ or BMI 27+ with comorbidities, not just difficulty losing weight
  • Monthly costs range from $900-1,200 without insurance coverage for brand-name versions
  • True weight plateaus lasting years despite caloric restriction are medically rare and warrant endocrine evaluation

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok creator actually claim?

Tiffany (@teeheefunnay) says she's been stuck at 170 pounds despite consistent exercise and healthy eating for years. She mentions high cholesterol and claims her doctor suggested GLP-1 medication not just for weight loss but for "overall health benefits in lowering everything."

The video positions GLP-1s as a solution for both weight plateaus and cholesterol management. She frames this as medical advice from her doctor rather than her own research.

This reflects a common narrative we're seeing on social media where creators present GLP-1s as multi-purpose health optimizers.

Does the science support GLP-1s for cholesterol?

The cholesterol benefits are real but modest. The STEP 1 trial (Wilding et al., NEJM, 2021) found semaglutide 2.4mg reduced LDL cholesterol by 9.6mg/dL compared to placebo over 68 weeks.

The SELECT trial (Lincoff et al., NEJM, 2023) showed semaglutide reduced cardiovascular events by 20% in people with existing heart disease. But this was likely due to weight loss effects, not direct cholesterol-lowering action.

These aren't dramatic cholesterol improvements. A statin like atorvastatin typically reduces LDL by 30-50%, making it far more effective for cholesterol management than any GLP-1.

What did she get wrong about weight plateaus?

Tiffany suggests her weight "won't go down" despite years of effort, implying metabolic dysfunction that requires medication. This oversimplifies how weight loss actually works.

Weight plateaus at 170 pounds don't indicate medical necessity for GLP-1s. The STEP trials enrolled people with BMIs of 30+ or 27+ with comorbidities. Without knowing Tiffany's height, we can't assess if she meets clinical criteria.

The "eating pretty healthy" claim is particularly problematic. Most people underestimate caloric intake by 20-40% according to nutrition research. A true plateau lasting years would be extremely rare without underlying medical conditions.

Are there legitimate reasons to consider GLP-1s?

If Tiffany actually has obesity (BMI 30+) plus high cholesterol, GLP-1s could be appropriate. The STEP trials showed 14.9% weight loss at 68 weeks with semaglutide 2.4mg.

But the "overall health benefits" framing is oversold. These medications work primarily through appetite suppression and slower gastric emptying. The cardiovascular benefits stem from weight loss, not independent metabolic effects.

Real candidates typically have failed multiple diet attempts, have obesity-related health conditions, and understand the $1,000+ monthly cost plus potential side effects like nausea and gastroparesis.

What should you actually know about GLP-1s?

Don't expect GLP-1s to fix everything. They're appetite suppressants that help some people eat less, not metabolic cure-alls that "lower everything."

The weight loss averages 15% in clinical trials, but 10-15% of people don't respond at all. About 5-10% stop due to gastrointestinal side effects in the first few months.

For cholesterol specifically, you'll get much better results from a $10/month statin than a $1,000/month GLP-1. These medications work best when combined with lifestyle changes, not as replacements for them.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Tiffany Shu · TikTok creator

54.3K views on this video

The most vulnerable journey I’ll be sharing online- Ive had an issue with my weight for my whole life… being too skinny then being too fat. 5 years ago I decided to make a life style change and I’ve b

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about step 1 trial showed semaglutide 2.4mg caused 14.9% weight loss?

STEP 1 trial showed semaglutide 2.4mg caused 14.9% weight loss over 68 weeks, but 10-15% of people don't respond

What does the video say about glp-1s reduce ldl cholesterol by only 9.6mg/dl compared to 30-50%?

GLP-1s reduce LDL cholesterol by only 9.6mg/dL compared to 30-50% reductions seen with statins

What does the video say about select trial found 20% cardiovascular risk reduction,?

SELECT trial found 20% cardiovascular risk reduction, but this was likely due to weight loss rather than direct metabolic effects

What does the video say about about 5-10% of people stop glp-1s due to gastrointestinal side?

About 5-10% of people stop GLP-1s due to gastrointestinal side effects like nausea and gastroparesis

What does the video say about clinical criteria typically require bmi 30+?

Clinical criteria typically require BMI 30+ or BMI 27+ with comorbidities, not just difficulty losing weight

What does the video say about monthly costs range from $900-1,200 without insurance coverage for brand-name?

Monthly costs range from $900-1,200 without insurance coverage for brand-name versions

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Tiffany Shu, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.